- Groundbreaking achievement in micro-transfer printing increases
density of Rockley’s silicon-photonics-based integrated lasers
beyond previous levels
- Lays foundation for continued photonic chip size reduction and
additional reductions in chip manufacturing costs
- Presents potential new commercial opportunities for Rockley,
including ultra-small wearables, clothing, or XR/AR/VR headsets and
glasses
- New chip technology will not impact timing of upcoming launch
of Bioptx™ biosensing band or other current-generation
products
Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”), a
global leader in photonics-based health monitoring and
communications solutions, today announced that it has developed
what it believes to be the world’s first micro-transfer-printed
(mTP) silicon-photonics-based laser for commercial applications.
This groundbreaking achievement is expected to allow Rockley to
further increase the density and reduce the size of its
high-density spectrophotometer chips — which are already the
world’s smallest for broadband infrared wavelength laser
spectrometry (covering 1000 nanometers of spectrum) and are smaller
in area than LED-based solutions currently used in wearables.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220922005112/en/
Size comparison of Rockley’s new mTP
laser array (Graphic: Business Wire)
This advancement could potentially have a significant impact
across a wide range of applications, including the design of
exceptionally small wearable devices for the detection and
measurement of multiple biomarkers. New silicon-photonics-based
biosensing chips using mTP technology are expected to be available
in the first half of 2024. The new chip technology should have no
impact on the upcoming launch of Rockley’s Bioptx™ biosensing band
nor on any current-generation products that Rockley and its
customers are developing.
With this breakthrough in the mTP of silicon-photonics-based
lasers, Rockley has dramatically increased the laser density of its
photonics integrated circuits (PICs) for biosensing, creating what
it believes to be the world’s highest-density broad-wavelength
laser spectrophotometer chip, surpassing its own previous
achievements. Moreover, the mTP process is expected to reduce
manufacturing costs and enable thinner, smaller footprint and
higher-density chip designs. These attributes are powerful benefits
for use in consumer and medtech devices and could facilitate the
integration of Rockley’s biosensing technology into future tiny
wearables.
Leveraging the mTP process, the new PIC technology will
integrate a laser-generating “membrane” with a thickness of only 4
microns. The potential applications for this higher-density and
smaller-footprint chip technology extend beyond biosensing and
health monitoring into other areas, such as ultra-small wearables,
clothing, or XR/VR/AR headsets and glasses.
This mTP breakthrough is the direct result of Rockley’s
multi-year partnership with the Tyndall National Institute at
University College Cork in Ireland, X-Celeprint Limited, and the
Irish Photonics Integration Centre (IPIC), with funding support
from the Irish government’s Science Foundation Ireland (SFI) and
Disruptive Technologies Innovation Fund (DTIF). The project started
five years ago with a focus on developing a custom mTP process for
Rockley’s silicon photonics platform and has involved a
multidisciplinary team of world-class engineers and researchers.
This technology, along with many other Rockley innovations, is
backed by a robust multidisciplinary patent portfolio of over 200
issued patents and 295 pending patents in total.
“Applying the micro-transfer printing process to the production
of integrated lasers is a huge breakthrough that we believe will
have a tremendous impact on wearable biosensing and on the
photonics industry as a whole,” said Dr. Andrew Rickman, chairman
and chief executive officer of Rockley. “We arguably have some of
the most sophisticated photonics technology in the world, and this
unprecedented level of miniaturization raises the bar even further.
By creating biosensing chips that are smaller, lower-cost, and more
efficient, we can continually improve our wearable biosensing
products and deliver novel, relevant, and more powerful ways to
monitor our health.”
“I believe that this next-gen, heterogeneous integration
platform will lead to several significant technological
advancements, including higher densities of lasers, increasingly
smaller chip sizes, and ultra-high-volume manufacturing,” said
Aaron Zilkie, chief technology officer of photonics at Rockley.
“The team has been working on this project for years, and we are
extremely excited to have reached this important milestone. We are
grateful for the close collaboration we’ve had with our research
partners and for the funding support from the Irish government and
its Science Foundation Ireland and Disruptive Technologies
Innovation Fund.”
About Rockley Photonics
A global leader in photonics-based health monitoring and
communications solutions, Rockley Photonics is developing a
comprehensive range of photonic integrated circuits and associated
modules, sensors, and full-stack solutions. From next-generation
sensing platforms specifically designed for mobile health
monitoring and machine vision to high-speed, high-volume solutions
for data communications, Rockley is laying the foundation for a new
generation of applications across multiple industries. Rockley
believes that photonics will eventually become as pervasive as
micro-electronics, and it has developed a platform with the power
and flexibility needed to address both mass markets and a wide
variety of vertical applications.
Formed in 2013, Rockley is uniquely positioned to support
hyper-scale manufacturing and address a multitude of high-volume
markets. Rockley has partnered with numerous tier-1 customers
across a diverse range of industries to deliver the complex optical
systems required to bring transformational products to market.
To learn more about Rockley, visit rockleyphotonics.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release that are not historical facts
constitute “forward-looking statements” for purposes of the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include statements
regarding Rockley’s future expectations, beliefs, plans,
objectives, and assumptions regarding future events or performance.
The words “accelerate,” “advance,” “anticipate,” “believe,” “can,”
“capability,” “continue,” “could,” “develop,” “enable,” “enhance”,
“estimate,” “eventual,” “expand, “expect,” “focus,” “forward,”
“future,” “goal,” “ground-breaking” “intend,” “may,” “might,”
“opportunity,” “outlook,” “plan,” “possible,” “position,”
“potential,” “predict,” “project,” “revolutionize,” “seem,”
“should,” “trend,” “vision,” “will,” “would” or other terms that
predict or indicate future events, trends, or expectations, and
similar expressions or the negative of such expressions may
identify forward-looking statements, but the absence of these words
or terms does not mean that a statement is not forward-looking.
Forward-looking statements in this press release include, but are
not limited to, statements regarding the following: (a) the
potential of Rockley’s sensing platform to provide a complete
end-to-end solution that enables the non-invasive, continuous, and
near-real-time monitoring of multiple biomarkers; (b) our belief
that we have developed the world’s first commercial
micro-transfer-printed laser and the world’s highest density
spectrometry chips for wearable health monitoring, and our belief
that these developments will produce significant additional
reductions in chip manufacturing costs, improve power efficiency,
potentially enhance performance of our products, and present new
commercial opportunities and applications; (c) the timing of the
availability of our products and technology; (d) our belief that we
are laying the foundation for a new generation of applications
across multiple industries, and the extent to which we may expand
our focus beyond biosensing solutions; (e) our belief that
photonics will eventually become as pervasive as micro-electronics;
and (f) our potential to support hyper-scale manufacturing, address
a multitude of high-volume markets, and deliver the complex optical
systems required to bring transformational products to market.
Forward-looking statements are subject to several risks,
assumptions, and uncertainties (many of which are beyond Rockley’s
control) that may cause actual results or performance to differ
materially from those expressed or implied by these forward-looking
statements. These risks, assumptions, and uncertainties include,
but are not limited to, the factors described under the heading
“Risk Factors” in our Annual Report on Form 10-K for the year ended
December 31, 2021, and in other documents we file with the
Securities and Exchange Commission. If any of these risks or
uncertainties materialize, or should any of these assumptions prove
incorrect, actual results may differ materially from those
discussed in or implied by these forward-looking statements. There
can be no assurance that future developments affecting Rockley will
be those that have been anticipated. Given these risks and
uncertainties, you should not place undue reliance on these
forward-looking statements. These forward-looking statements speak
only as of the date hereof and Rockley does not intend to update or
revise any forward-looking statements, whether because of new
information, future events, or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220922005112/en/
Media Debra Raine Rainemakers Telephone: +1 415-349-7432 Email:
rockleyphotonics@rainemakers.com
Investors Gwyn Lauber Rockley Photonics Telephone: +1
626-995-0001 Email: investors@rockleyphotonics.com
Rockley Photonics (NYSE:RKLY)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Rockley Photonics (NYSE:RKLY)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
